%0 Journal Article
%T Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window
%A Tiffany N Eady
%A Larissa Khoutorova
%A Kristal D Atkins
%A Nicolas G Bazan
%A Ludmila Belayev
%J Experimental & Translational Stroke Medicine
%D 2012
%I BioMed Central
%R 10.1186/2040-7378-4-19
%X Sprague¨CDawley rats were received 2 h middle cerebral artery occlusion (MCAo). The behavior was evaluated on day 1, 2, 3 and 7 after MCAo. In the dose¨Cresponse study, animals were given either DHA (5mg/kg), Alb (0.63g/kg), DHA-Alb (5mg/kg + 0.32, 0.63 or 1.25 g/kg) or saline, i.v. 3 h after onset of stroke (n=6-8 per group). In the therapeutic window study, DHA-Alb (5mg/kg + 1.25g/kg) was administered i.v. at either 3, 4, 5, 6 or 7 h after onset of stroke (n=7-9 per group). Alb (1.25g/kg) was given at 3 h or 5 h and saline at 3h after onset of reperfusion. Seven days after MCAo, infarct volumes and number of GFAP, ED-1, NeuN, SMI-71 positive cells and vessels were counted.Moderate DHA-Alb doses (0.63 and 1.25 g/kg) improved neurological scores compared to albumin-treated rats on days 1, 2, 3 and 7. All DHA-Alb doses (0.32, 0.63 and 1.25 g/kg) markedly reduced cortical (by 65-70%), striatal (by 52-63%) and total infarct volumes (by 60-64%) compared to native Alb group. In the therapeutic window study DHA-Alb led to improved neurological score and significant reductions of infarct volumes (especially in the cortical or penumbral region), even when treatment was initiated as late as 7 hours after onset of MCAo.The DHA-Alb complex affords high-grade neurobehavioral neuroprotection in focal cerebral ischemia, equaling or exceeding that afforded by native Alb or DHA, at considerably moderate doses. It has a broad therapeutic window extending to 7 h after stroke onset. Taken together, these finding support the potential clinical feasibility of administering DHA-Alb therapy to patients with acute ischemic stroke.Stroke is a major cause of death and disability in industrialized countries. Pharmacological intervention of ischemic damage is critically important for controlling brain tissue deterioration. Tissue-type plasminogen activator (tPA) administered within 3 to 4.5 h of symptom onset is still the only thrombolytic agent approved for patients with ischemic stroke. Howeve
%K Penumbra
%K DHA-Alb complex
%K Neuroprotection
%K Behavior
%K Histopathology
%K Focal ischemia
%K Experimental stroke
%U http://www.etsmjournal.com/content/4/1/19